463 related articles for article (PubMed ID: 16626669)
1. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
Crocker SF; Costain WJ; Robertson HA
Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
[TBL] [Abstract][Full Text] [Related]
2. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease.
Desplats PA; Kass KE; Gilmartin T; Stanwood GD; Woodward EL; Head SR; Sutcliffe JG; Thomas EA
J Neurochem; 2006 Feb; 96(3):743-57. PubMed ID: 16405510
[TBL] [Abstract][Full Text] [Related]
3. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
[TBL] [Abstract][Full Text] [Related]
4. Striatal specificity of gene expression dysregulation in Huntington's disease.
Thomas EA
J Neurosci Res; 2006 Nov; 84(6):1151-64. PubMed ID: 16983659
[TBL] [Abstract][Full Text] [Related]
5. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.
Josefsen K; Nielsen MD; Jørgensen KH; Bock T; Nørremølle A; Sørensen SA; Naver B; Hasholt L
J Neuroendocrinol; 2008 Feb; 20(2):165-72. PubMed ID: 18034868
[TBL] [Abstract][Full Text] [Related]
6. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes.
Ariano MA; Wagle N; Grissell AE
J Neurosci Res; 2005 Jun; 80(5):634-45. PubMed ID: 15880743
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
Ebert AD; Barber AE; Heins BM; Svendsen CN
Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
[TBL] [Abstract][Full Text] [Related]
8. Gene expression in Huntington's disease skeletal muscle: a potential biomarker.
Strand AD; Aragaki AK; Shaw D; Bird T; Holton J; Turner C; Tapscott SJ; Tabrizi SJ; Schapira AH; Kooperberg C; Olson JM
Hum Mol Genet; 2005 Jul; 14(13):1863-76. PubMed ID: 15888475
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
Petersén A; Chase K; Puschban Z; DiFiglia M; Brundin P; Aronin N
Exp Neurol; 2002 May; 175(1):297-300. PubMed ID: 12009780
[TBL] [Abstract][Full Text] [Related]
10. Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice.
Petersén A; Stewénius Y; Björkqvist M; Gisselsson D
BMC Cell Biol; 2005 Sep; 6():34. PubMed ID: 16159402
[TBL] [Abstract][Full Text] [Related]
11. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.
Saavedra A; García-Martínez JM; Xifró X; Giralt A; Torres-Peraza JF; Canals JM; Díaz-Hernández M; Lucas JJ; Alberch J; Pérez-Navarro E
Cell Death Differ; 2010 Feb; 17(2):324-35. PubMed ID: 19745829
[TBL] [Abstract][Full Text] [Related]
12. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
13. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
Bailey CD; Johnson GV
J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
[TBL] [Abstract][Full Text] [Related]
14. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.
Ribchester RR; Thomson D; Wood NI; Hinks T; Gillingwater TH; Wishart TM; Court FA; Morton AJ
Eur J Neurosci; 2004 Dec; 20(11):3092-114. PubMed ID: 15579164
[TBL] [Abstract][Full Text] [Related]
15. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
Wade A; Jacobs P; Morton AJ
Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
[TBL] [Abstract][Full Text] [Related]
16. Striatal potassium channel dysfunction in Huntington's disease transgenic mice.
Ariano MA; Cepeda C; Calvert CR; Flores-Hernández J; Hernández-Echeagaray E; Klapstein GJ; Chandler SH; Aronin N; DiFiglia M; Levine MS
J Neurophysiol; 2005 May; 93(5):2565-74. PubMed ID: 15625098
[TBL] [Abstract][Full Text] [Related]
17. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
18. Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat.
Winkler C; Gil JM; Araújo IM; Riess O; Skripuletz T; von Hörsten S; Petersén A
Brain Res Bull; 2006 Apr; 69(3):306-10. PubMed ID: 16564426
[TBL] [Abstract][Full Text] [Related]
19. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
20. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment.
Rebec GV; Conroy SK; Barton SJ
Neuroscience; 2006; 137(1):327-36. PubMed ID: 16257492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
